<DOC>
	<DOCNO>NCT00847366</DOCNO>
	<brief_summary>This open label trial patient currently enrol perifosine trial .</brief_summary>
	<brief_title>Open Label Trial Perifosine Patients Currently Being Treated Perifosine Trials Solid Tumors Multiple Myeloma</brief_title>
	<detailed_description>Perifosine oral anticancer agent limited toxicity novel mechanism action distinctly different cytotoxic chemotherapy . It show inhibit otherwise modify signal number pathway include Akt , p21 , JNK . Perifosine test Phase I Phase II setting variety dose schedule include daily , weekly , daily follow load dose . In general , well tolerate dose-related nausea , vomit , diarrhea , fatigue commonly observe toxicity . Perifosine induce partial response stable disease solid tumor include limited renal cell , sarcoma , hepatocellular carcinoma . Perifosine currently study multiple disease single agent well combination cancer therapy . As study close patient achieve partial response stable disease .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<criteria>Patients must currently receive treatment perifosine previously approve protocol . Patients must least one evaluation follow initiation treatment stable disease , partial response complete response . Patient willing sign new consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Perifosine</keyword>
</DOC>